Lupus News and Research RSS Feed - Lupus News and Research

Systemic lupus erythematosus (SLE), also called lupus, is an autoimmune disorder characterized by the immune system attacking the body's own tissues and organs, leading to inflammation and damage. The severity of the disease varies, from mild cases only involving the skin to severe cases affecting multiple organs, including the brain. Lupus sufferers experience flares, or intervals of active disease, and remissions in disease. The disease most predominantly occurs in women of childbearing age, but also affects children, adolescents, and men. While the cause of lupus is still unknown, various genetic, environmental, and infectious causes have been associated with its development. Current treatments for lupus vary depending on the extent of the disease, and may change over time. Some medications used to ease symptoms include nonsteroidal anti-inflammatory drugs, antimalarial drugs, corticosteroids, and immunosuppressive medications, though many of these drugs carry their own risks.
African-American patients with connective tissue diseases at risk for cardiovascular disease

African-American patients with connective tissue diseases at risk for cardiovascular disease

A study based on medical records from more than a quarter million adult patients found that African-American patients with connective tissue diseases such as lupus or rheumatoid arthritis were twice as likely as white patients to suffer from narrowed or atherosclerotic blood vessels, which increase the risk of a heart attack, stroke or death. [More]
IMP, WEHI scientists successfully characterize central regulator of plasma cell function

IMP, WEHI scientists successfully characterize central regulator of plasma cell function

Plasma cells play a key role in our immune system. Now scientists at the Research Institute of Molecular Pathology (IMP) in Vienna, Austria, and at the Walter and Eliza Hall Institute (WEHI) in Melbourne, Australia, succeeded in characterizing a central regulator of plasma cell function. [More]
Novel anti-inflammatory agents could control hyper-inflammatory responses to fungal infection

Novel anti-inflammatory agents could control hyper-inflammatory responses to fungal infection

The most frequent fungal threat to humans, Candida albicans, is a common cause oral and genital infection. The fungal infections are often worsened by overwhelming inflammatory responses in the body and cause high mortality among risk groups. Umeå University doctoral student Ava Hosseinzadeh has discovered two novel anti-inflammatory agents, an antioxidant and an anti-inflammatory molecule, which could be used to control the hyper-inflammatory responses to the fungal infection. [More]
Genetic factors in puberty timing: an interview with Dr John Perry

Genetic factors in puberty timing: an interview with Dr John Perry

The study focused on the genetic regions that influence age at voice breaking - a distinct developmental milestone that happens to young men as their larynx (voice box) lengthens when exposed to male hormones. [More]
UF researchers reveal link between chronic stress and fat metabolism

UF researchers reveal link between chronic stress and fat metabolism

In cell and mouse model experiments, University of Florida Health researchers have discovered that chronic stress stimulates production of betatrophin, a protein that then goes on to inhibit an enzyme involved in fat metabolism. [More]
Processed foods may increase likelihood of developing autoimmune diseases

Processed foods may increase likelihood of developing autoimmune diseases

In today's hustle and bustle world, processed foods are commonplace time-savers. But that convenience factor may come with a bigger price tag than previously known, says an international team of researchers. [More]
Diseases that cause skin-related problems can also trigger serious neurological conditions

Diseases that cause skin-related problems can also trigger serious neurological conditions

Diseases such as lupus that cause rashes and other skin problems also can trigger migraine headaches, strokes and other serious neurological conditions, according to an article by Loyola University Medical Center physicians. [More]
Lupuzor may become first non-immunosuppressant therapy for lupus

Lupuzor may become first non-immunosuppressant therapy for lupus

Lupuzor may become the first specific and non-immunosuppressant therapy for lupus, a disabling autoimmune disease that is currently incurable. [More]
Vagus nerve stimulation prevents hemorrhagic complications following surgery

Vagus nerve stimulation prevents hemorrhagic complications following surgery

Stimulating the vagus nerve is a potentially efficacious and safe way to stop the flow of blood and prevent hemorrhagic complications following surgery and other invasive procedures, according to a researcher in the Center for Bioelectronic Medicine at The Feinstein Institute for Medical Research. [More]
Plasmacytoid dendritic cells may not contribute to late-stage lupus

Plasmacytoid dendritic cells may not contribute to late-stage lupus

For years, biomedical researchers have suspected that a specific set of immune cells are responsible for causing disease in lupus patients, but until now they haven't known for sure one way or the other. [More]
TTUHSC nephrologists to help find new treatment for lupus nephritis

TTUHSC nephrologists to help find new treatment for lupus nephritis

Nephrologists at Texas Tech University Health Science Center El Paso have been invited to participate in a national consortium that's investigating the key causes of lupus nephritis -- an autoimmune disease that can cause kidney failure. [More]
Mallinckrodt Study Shows Acthar® Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus

Mallinckrodt Study Shows Acthar® Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus

Data presented yesterday by researchers for Mallinckrodt plc, a leading specialty biopharmaceutical company, suggest that H.P. Acthar® Gel (repository corticotropin injection) reduces certain measures of disease activity in patients with persistently active Systemic Lupus Erythematosus (SLE) who are receiving corticosteroid therapy. [More]
HSS researchers help identify lupus patients at increased risk of problem pregnancies

HSS researchers help identify lupus patients at increased risk of problem pregnancies

For years doctors have been advising patients with lupus not to get pregnant. It was assumed that the likelihood of pregnancy complications was too high in this population. However, ongoing work by researchers at Hospital for Special Surgery is helping identify those lupus patients who are - and aren't - at increased risk of problem pregnancies. [More]
New funding for Centenary's life saving research

New funding for Centenary's life saving research

The Centenary Institute has welcomed the Federal Government’s announcement of funding for 9 new and innovative medical research projects via the latest round of NHMRC grant rounds funding, officially confirmed today. [More]
Researchers identify role of cGAS enzyme in autoimmune diseases

Researchers identify role of cGAS enzyme in autoimmune diseases

Activating an enzyme that sounds an alarm for the body's innate immune system causes two lethal autoimmune diseases in mice, while inhibiting the same enzyme rescues them, UT Southwestern Medical Center researchers report. [More]
XTL signs agreement with Yeda to amend development milestones for lupus treatment

XTL signs agreement with Yeda to amend development milestones for lupus treatment

XTL Biopharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of unmet clinical needs with a focus on treatments for autoimmune diseases, today announced that it has reached agreement with Yeda Research and Development Company Ltd. to amend the development milestones in the License Agreement signed between the parties in January 2014 for the development of hCDR1 for the treatment of systemic lupus erythematosus (SLE). [More]
ImmunArray launches SLE-key Rule-Out test for lupus patients

ImmunArray launches SLE-key Rule-Out test for lupus patients

Following a limited three-month trial period in which more than one hundred and fifty patients with lupus-like symptoms were tested for the difficult-to-diagnose disease, a new blood test for lupus is being rolled out nationally. [More]
Scientists calculate precise measurements of heritability in nine pediatric-onset autoimmune diseases

Scientists calculate precise measurements of heritability in nine pediatric-onset autoimmune diseases

Scientists have calculated more precise measurements of heritability--the influence of underlying genes--in nine autoimmune diseases that begin in childhood. The research may strengthen researchers' abilities to better predict a child's risk for associated autoimmune diseases. [More]
Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

New results from a Phase II head-to-head psoriasis study showed superior efficacy of Boehringer Ingelheim's investigational biologic compound BI 655066, over ustekinumab. After nine months, 69 percent of patients with moderate-to-severe plaque psoriasis maintained clear or almost clear skin (PASI 90) with BI 655066 in the higher dose group compared to 30 percent of patients on ustekinumab. [More]
Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Mallinckrodt plc, a leading specialty biopharmaceutical company, today announced that data from a pilot study for its H.P. Acthar Gel (repository corticotropin injection) will be presented at the American College of Rheumatology 2015 Annual Meeting to be held November 7-11 in San Francisco. [More]
Advertisement